EUVIMEDEUVIMED entdecken
Übersichtsarbeit

MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact

Meik Kunz, Claudia Göttlich, Thorsten Walles, Sarah Nietzer, Gudrun Dandekar, Thomas Dandekar

Tumor Biology · 2017-07 · 39 (7) · 101042831770643

DOI: 10.1177/1010428317706430 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumor Biology, online erschienen am 14.07.2017. Verfasst von Meik Kunz und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1 Functional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter, Würzburg, Germany. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 164 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorComputational BiologyDisease ProgressionGene Expression Regulation, NeoplasticHumansLung NeoplasmsMicroRNAsPrognosis

Stichwörter der Autor:innen

MicroRNAsbioinformaticsbiomarkerlung cancermicroRNA–target interactiontherapeutic strategy

Substanzen

Biomarkers, TumorMIRN21 microRNA, humanMIRN34 microRNA, humanMicroRNAs

Autor:innen und Institutionen

  • 1 Functional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter, Würzburg, Germany.
  • 2 Department of Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Würzburg, Germany.
  • 3 Department of Cardiothoracic Surgery, University Hospital Magdeburg, Magdeburg, Germany.
  • 4 Translational Center Würzburg "Regenerative Therapies in Oncology and Musculoskeletal Disease", Branch of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Würzburg, Germany.

Zitieren

APA

Kunz, M., Göttlich, C., Walles, T., Nietzer, S., Dandekar, G., & Dandekar, T. (2017). MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology, 39(7), 101042831770643. https://doi.org/10.1177/1010428317706430

Vancouver

Kunz M, Göttlich C, Walles T, Nietzer S, Dandekar G, Dandekar T. MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology. 2017;39(7):101042831770643. doi:10.1177/1010428317706430

BibTeX
@article{Kunz2017,
  author = {Kunz, Meik and Göttlich, Claudia and Walles, Thorsten and Nietzer, Sarah and Dandekar, Gudrun and Dandekar, Thomas},
  title = {MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact},
  journal = {Tumor Biology},
  year = {2017},
  volume = {39},
  number = {7},
  pages = {101042831770643},
  doi = {10.1177/1010428317706430}
}
Kostenlos starten →